A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis (XPORT-MF-034)

被引：2
|
作者：
Maher, Keri [1 ]
Rampal, Raajit K. [2 ]
Bose, Prithviraj [3 ]
Podoltsev, Nikolai A. [4 ]
Harrison, Claire N. [5 ]
Hong, Junshik [6 ]
Wang, Xulong [7 ]
Chamoun, Kamal [7 ]
Mascarenhas, John [8 ]
机构：
[1] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[4] Yale Sch Med, Dept Hematol, Med, New Haven, CT USA
[5] Guys & St Thomas NHS Fdn Trust, London, England
[6] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Seoul, South Korea
[7] Karyopharm Therapeut, Newton, MA USA
[8] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, Dept Med, New York, NY USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180695
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
634
引用
收藏
页数：4
相关论文
共 50 条
  • [1] A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Patients with JAK Inhibitor-Naive Myelofibrosis and Moderate Thrombocytopenia (XPORT-MF-044)
    Scandura, Joseph M.
    Gerds, Aaron T.
    Ritchie, Ellen K.
    Wang, Xulong
    Kye, Steve
    Rampal, Raajit K.
    BLOOD, 2023, 142
  • [2] Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi) Treatment-Naive Patients With Myelofibrosis: Updated Results and Subgroup Analyses from XPORT-MF-034
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay
    Prchal, Josef
    Wang, Xulong
    Chamoun, Kamal
    Tantravahi, Srinivas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S389 - S389
  • [3] Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naive patients with myelofibrosis: Updated results from XPORT-MF-034
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri Renee
    Mohan, Sanjay
    Prchal, Josef T.
    Wang, Xulong
    Chamoun, Kamal
    Tantravahi, Srinivas Kiran
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naive Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification
    Tantravahi, Srinivas K.
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay
    Prchal, Josef T.
    Wang, Xulong
    Chamoun, Kamal
    Walker, Christopher J.
    Taverna, Pietro
    Ali, Haris
    BLOOD, 2023, 142
  • [5] Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naive myelofibrosis.
    Mascarenhas, John
    Maher, Keri Renee
    Rampal, Raajit
    Bose, Prithviraj
    Podoltsev, Nikolai Alexandrovich
    Hong, Junshik
    Wang, Xulong
    Kye, Steve
    Harrison, Claire
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
    Rampal, Raajit K.
    Grosicki, Sebastian
    Chraniuk, Dominik
    Abruzzese, Elisabetta
    Bose, Prithviraj
    Gerds, Aaron T.
    Vannucchi, Alessandro M.
    Palandri, Francesca
    Lee, Sung-Eun
    Gupta, Vikas
    Lucchesi, Alessandro
    Oh, Stephen T.
    Kuykendall, Andrew T.
    Patriarca, Andrea
    alvarez-Larran, Alberto
    Mesa, Ruben
    Kiladjian, Jean-Jacques
    Talpaz, Moshe
    Scandura, Joseph M.
    Lavie, David
    Harris, Morgan
    Kays, Sarah-Katharina
    Li, Qing
    Boxhammer, Rainer
    Brown, Barbara
    Jegg, Anna-Maria
    Harrison, Claire N.
    Mascarenhas, John
    NATURE MEDICINE, 2025,
  • [7] Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naive Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
    Mascarenhas, John
    Rampal, Raajit K.
    Grosicki, Sebastian
    Chraniuk, Dominik
    Abruzzese, Elisabetta
    Bose, Prithviraj
    Gerds, Aaron
    Vannucchi, Alessandro M.
    Palandri, Francesca
    Lee, Sung-Eun
    Gupta, Vikas
    Lucchesi, Alessandro
    Oh, Stephen T.
    Kuykendall, Andrew T.
    Patriarca, Andrea
    Alvarez-Larran, Alberto
    Mesa, Ruben
    Kiladjian, Jean-Jacques
    Talpaz, Moshe
    Lavie, David
    Harris, Morgan
    Kays, Sarah-Katharina
    Jegg, Anna Maria
    Wu, Manlei
    Brown, Barbara
    Harrison, Claire
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S416 - S417
  • [8] POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naive Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
    Vachhani, Pankit
    Rampal, Raajit
    Bradley, Terrence
    Harrison, Claire
    Jain, Tania
    Kuykendall, Andrew T.
    Palandri, Francesca
    Mascarenhas, John O.
    Al-Ali, Haifa Kathrin
    Passamonti, Francesco
    Nekhymchuk, Anna
    Foss, Hilarie
    Rothbaum, Wayne
    Verstovsek, Srdan
    Heidel, Florian
    BLOOD, 2024, 144 : 18083 - 18084
  • [9] Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.
    Passamonti, Francesco
    Foran, James M.
    Tandra, Anand
    De Stefano, Valerio
    Fox, Maria Laura
    Mattour, Ahmad Hatem
    McMullin, Mary Frances
    Perkins, Andrew
    Rodriguez-Macias, Gabriela
    Sibai, Hassan
    Qin, Qin Q.
    Potluri, Jalaja
    How, Jonathan B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients
    Mascarenhas, John
    Harrison, Claire
    Luptakova, Katarina
    Christo, Jessica
    Wang, Jing
    Mertz, Jennifer A.
    Colak, Gozde
    Shao, James
    Bobba, Suresh
    Trojer, Patrick
    Senderowicz, Adrian
    Humphrey, Jeffrey S.
    Verstovsek, Srdan
    BLOOD, 2020, 136
12345